A recent clinical trial, BRILLIANCE demonstrated the safety and efficacy of CRISPR gene editing in treating inherited blindness caused by mutations in the CEP290 gene. The study involved 14 participants who received a single injection of the CRISPR/Cas9-based medicine, EDIT-101, which showed measurable improvements in 11 participants' vision.
A recent clinical trial, BRILLIANCE demonstrated the safety and efficacy of CRISPR gene editing in treating inherited blindness caused by mutations in the CEP290 gene. The study involved 14 participants who received a single injection of the CRISPR/Cas9-based medicine, EDIT-101, which showed measurable improvements in 11 participants' vision.
Share this Article
Recommended